NanoVibronix (NanoVibronix) ROCE %

: -66.95% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NanoVibronix's annualized ROCE % for the quarter that ended in Dec. 2023 was -66.95%.

NanoVibronix ROCE % Historical Data

The historical data trend for NanoVibronix's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoVibronix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-447.92

-119.76

-236.59

-98.54

-91.15

NanoVibronix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-194.39	-139.49	-206.48	-85.72	-66.95

NanoVibronix ROCE % Calculation

NanoVibronix's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.547	/	( ( (5.879 - 2.316)	+	(6.674 - 2.454) )	/ 2 )
	=	-3.547	/	( (3.563	+	4.22)	/ 2 )
	=	-3.547	/	3.8915
	=	-91.15 %

NanoVibronix's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-3.076	/	( ( (7.361 - 2.392)	+	(6.674 - 2.454) )	/ 2 )
	=	-3.076	/	( ( 4.969	+	4.22 )	/ 2 )
	=	-3.076	/	4.5945
	=	-66.95 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

NanoVibronix (NAS:NAOV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NanoVibronix ROCE % Related Terms

Thank you for viewing the detailed overview of NanoVibronix's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

NanoVibronix (NanoVibronix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoVibronix Inc (NAS:NAOV) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

56R0:Germany

Address

525 Executive Boulevard, Elmsford, New York, NY, USA, 10523

Website

https://www.nanovibronix.com

NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low frequency, low intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

Executives

Christopher M Fashek	director	8023 VANTAGE DR, SAN ANTONIO TX 78230
Stephen Russell Brown	officer: Chief Financial Officer	18-B NEIL COURT, OCEANSIDE NY 11572
Aurora Cassirer	director	C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Maria Schroeder	director	C/O NANOVIBRONIX, INC.,, 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Brian M Murphy	director, officer: Chief Executive Officer	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Michael Ferguson	director	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Thomas Mika	director	TEGAL CORP, 2201 SOUTH MCDOWELL BLVD, PETALUMA CA 94954
Ira A Greenstein	director	IDT CORP, 520 BROAD STREET, NEWARK NJ 07102
Harold Jacob	director, officer: Chief Medical Officer	HAADMUR MEBUYON 26, HARNOT, JERUSALEM L3 95403
Martin M Goldstein	director	C/O NANOVIBRONIX, INC., 525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
William Stern	director, officer: Chief Executive Officer	525 EXECUTIVE BOULEVARD, ELMSFORD NY 10523
Jona Zumeris	director, officer: VP of Technology	105 MAXESS ROAD, SUITE S124, MELVILLE NY 11747
Miriam W Kelly	10 percent owner	P.O. BOX 1443, BROOKLANDVILLE MD 21022